drug · Product Intelligence

Gabapentin
Pipeline Intelligence

Gabapentin: 9 indexed trials, 7 sponsors; 0 linked Orange Book patents and 9 FDA-linked events where matched.

⚗

9Indexed trials

▦

7Sponsors

⌁

0Orange Book patent links

◎

9FDA-linked events

NCT00620555Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · epilepsyPHASE3

NCT00785772Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · epilepsyPHASE4

NCT01893632New York State Psychiatric Institute · out_of_scopePHASE2

NCT03023501King Saud University · out_of_scopePHASE2

NCT03589898University of Massachusetts, Worcester · autismEARLY_PHASE1

NCT03635905Medstar Health Research Institute · pain_neuropathyPHASE4

NCT04345432Medstar Health Research Institute · other_neurologyNA

NCT05172570Indiana University · pain_neuropathyPHASE3

NCT05664464University of Zurich · epilepsyPHASE1, PHASE2

Orange Book match found; no listed patent relation was retained for this product match.

FDA_APPROVALGABAPENTIN · 2026-03-06

FDA_APPROVALGABAPENTIN · 2025-08-25

FDA_APPROVALGABAPENTIN · 2024-05-29

FDA_APPROVALGABAPENTIN · 2018-05-14

FDA_APPROVALGABAPENTIN · 2013-07-03

FDA_APPROVALGABAPENTIN · 2012-10-16

FDA_APPROVALGABAPENTIN · 2011-02-18

FDA_APPROVALGABAPENTIN · 2006-01-24

FDA_APPROVALNEURONTIN · 1993-12-30

FDA Orange Book coverage is U.S.-specific and is not a substitute for worldwide patent or regulatory review.

GabapentinPipeline Intelligence